Abstract: An adaptable connector, a non-standard PCIe module, and a computer readable medium are disclosed. The adaptable connector for a PCIe interface allows for multiple standard PCIe modules and non-standard PCIe modules at different times An external I/O port has a set of non-PCIe I/O signal lanes coupled to the adaptable connector in lieu of a set of root port host PCIe signal lanes when a non-standard PCIe module is mated to the adaptable connector.

Abstract: Examples associated with boot authentication are described. One example includes initiating a power on self-test (POST) phase of a boot of a system. Prior to initiating a driver execution environment phase of the POST phase, a network stack may be loaded for a network port. An encrypted key may be retrieved from a trusted component of the system. Boot of the system may be permitted to proceed upon establishing a connection with an authentication server, and authenticating the system to the authentication server based on the encrypted key.

Abstract: In an example, radio frequency identification communications is used to pair a wireless device and a host computing system for communications over a non-radio frequency identification communications protocol. The wireless device includes a radio frequency identification reader that extracts pairing information from a radio frequency identification tag of the host computing system. The wireless device may then automatically initiate pairing with the host computing system using the pairing information, without further input from a user of the wireless device. A connection is then established between the wireless device and the host computing system using a non-radio frequency identification wireless communication protocol. The connection facilitates an exchange of data between the wireless device and the host computing system.

Abstract: An apparatus includes a memory card that includes at least one memory module and an expansion connector to connect with at least one expansion memory card. A lane distributor on the memory card interfaces with a set of bidirectional lanes and provides a base lane set and an expanded lane set of bidirectional lanes to support communications with the memory module and the expansion memory card via the expansion connector.

Abstract: Examples disclosed herein relate to data channel allocation. An example includes an apparatus, including a resource to connect to a controller in a first state and a peripheral card in a second state. Example apparatus include a controller to control a connection to an interface card and to connect to the resource via a first data channel in the first state, the first data channel to connect the resource and the peripheral card in the second state.

Abstract: A method for controlling an unmanned aerial vehicle (UAV) is described. In one example, the method includes: detecting, by one or more processors of a controller within a UAV, whether flight control surfaces of the UAV are operating nominally; switching, by the one or more processors of the controller, in response to detecting that one or more of the flight control surfaces of the UAV are not operating nominally, to implementing a backup control mode configured to operate the UAV in flight with non-nominal operability of one or more of the control surfaces of the UAV; and operating, by the one or more processors of the controller, the UAV in the backup control mode.

Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, and R5 are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.

Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R6 and A are as defined in the specification.

Abstract: The present invention relates to novel isoquinoline-3-carboxylic acid amides having ?7 nicotinic acetylcholine receptor agonistic activity, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.

Abstract: The invention provides compounds of formula (I) wherein X, Y, R1, R2, R3 and R4 are as defined in the description, and the preparation thereof.

Abstract: The invention provides compounds of formula (I) wherein R0, R1, R2 and A are as defined in the description, and the preparation thereof. The compounds of formula (I) have high affinity as ?2 adrenoceptors and hence are useful as pharmaceuticals.

Abstract: A gel material and medical articles including such material, wherein the transparent gel material includes a polymerized poly(alkylene oxide) macromonomer that, prior to polymerization, is free-radically polymerizable, multifunctional (preferably difunctional), and has an average molecular weight of at least about 2000.

Abstract: The invention provides compounds of formula I (I) wherein R1, R2, R3, R4 and R5 are as defined in the description, and the preparation thereof. The compounds of formula I are useful as pharmaceuticals.

Abstract: The invention provides compounds of formula (I) wherein X, Y, R1, R2, R3 and R4 are as defined in the description, and the preparation thereof. The compounds of the formula bind to somatostatin receptors and are useful as pharmaceuticals.

Abstract: The present invention provides compounds of formula (I), wherein X, Y, R1, R2, R3, and R4 are as defined in the description, and the preparation therof. The compounds of the formula bind to somatostatin receptiors and are useful as pharmaceuticals.

Abstract: The invention provides compounds of formula (I) wherein R0, R1, R2 and A are as defined in the description, and the preparation thereof. The compounds of formula (I) have high affinity as &agr;2 adrenoceptors and hence are useful as pharmaceuticals.

Abstract: The invention provides a compound of formula (I) wherein A, B, X, Y and R are as defined in the description, and a process for preparing them. The compounds of formula (I) arc useful as pharmaceuticals for the treatment of glaucoma and myopia.

Abstract: The invention provides compounds of formula I ##STR1## wherein X, Y, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are as defined in the description, and a process for preparing them. The compounds of formula I are useful as pharmaceuticals.

Abstract: (a) R.sub.1 and R.sub.5 are hydrogen and R.sub.3 is n-propyl, isobutyl, cyclopentylmethyl, benzyl or 2-(p-fluorophenyl)ethyl;(b) R.sub.1 is fluorine and R.sub.5 is hydrogen and R.sub.3 is n-propyl;(c) R.sub.1 is methyl and R.sub.5 is hydrogen and R.sub.3 is cyclopropylmethyl;(d) R.sub.1 is cyano and R.sub.5 is hydrogen and R.sub.3 is n-propyl;(e) R.sub.1 is hydrogen, R.sub.5 is methyl and R.sub.3 is alkyl of 2 to 5 carbon atoms, cycloalkylmethyl of 5 to 7 carbon atoms in the cycloalkyl part thereof or --(CH.sub.2).sub.n --R' wherein n is 0, 1 or 2 and R' is phenyl or monofluorophenyl; or(B) R is hydroxy, R.sub.1 is fluorine and R.sub.5 is hydrogen, and their physiologically hydrolysable derivatives, in which at least one hydroxy group is in esterifiedform, and their salts, elicit highly cardioselective beta 1 adrenoceptor blockade, and in most cases cardiospecific blockade, and relevant cardiotonic activity. These compounds can be used as therapeutic agents.